APO Research
Talk to an analyst

APO RESEARCH · REPORT

Transcriptomics

Transcriptomic incorporates the exploration and assortment of transcriptomes and finds diverse applications, chiefly in molecular genetics. The global transcriptomic market could see a whole lot of instances of new product launch. For example, Trio RNA-Seq launched by NuGEN Technologies, Inc. is particularly suited for low abundance transcripts applications as it offers an extremely sensitive whole transcriptomic solution. This innovation embodies three powerful technologies, viz. single primer isothermal amplification (SPIA), DimerFree, and AnyDeplete, for performing high sensitivity ribonucleic acid (RNA) analysis.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Transcriptomic incorporates the exploration and assortment of transcriptomes and finds diverse applications, chiefly in molecular genetics. The global transcriptomic market could see a whole lot of instances of new product launch. For example, Trio RNA-Seq launched by NuGEN Technologies, Inc. is particularly suited for low abundance transcripts applications as it offers an extremely sensitive whole transcriptomic solution. This innovation embodies three powerful technologies, viz. single primer isothermal amplification (SPIA), DimerFree, and AnyDeplete, for performing high sensitivity ribonucleic acid (RNA) analysis.

Selected research

Market Outlook & Growth Opportunities

Global Transcriptomics Market Outlook and Growth Opportunities 2026

20 December 2025192 pages

Choose your research edition.

Industry ResearchTranscriptomics Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Transcriptomics Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Transcriptomics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Transcriptomics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Transcriptomics Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Transcriptomic incorporates the exploration and assortment of transcriptomes and finds diverse applications, chiefly in molecular genetics. The global transcriptomic market could see a whole lot of instances of new product launch. For example, Trio RNA-Seq launched by NuGEN Technologies, Inc. is particularly suited for low abundance transcripts applications as it offers an extremely sensitive whole transcriptomic solution. This innovation embodies three powerful technologies, viz. single primer isothermal amplification (SPIA), DimerFree, and AnyDeplete, for performing high sensitivity ribonucleic acid (RNA) analysis.

North America is the largest consumption place, with a consumption market share nearly 55% . Following North America, Europe is the second largest consumption place with the consumption market share of 25% .The key manufacturers are Thermo Fisher Scientific, Illumina, QIAGEN (Exiqon), Agilent Technologies, Roche, GE Healthcare, Bio-Rad Laboratories, Fluidigm etc. Top 3 companies occupied about 41% market share.

This report provides an overview of the global Transcriptomics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Transcriptomics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Transcriptomics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Transcriptomics market.

Transcriptomics Segment by Company

Thermo Fisher Scientific

Illumina

QIAGEN (Exiqon)

Agilent Technologies

Roche

GE Healthcare

Bio-Rad Laboratories

Fluidigm

Transcriptomics Segment by Type

PCR

Microarray

Sequencing

Transcriptomics Segment by Application

Pharmaceutical and Biotechnology

Academic Research and Government Institutes

Hospitals and Diagnostic Centers

Transcriptomics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Transcriptomics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Transcriptomics key companies, revenue, market share, and recent developments.

3. To split the Transcriptomics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Transcriptomics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Transcriptomics significant trends, drivers, influence factors in global and regions.

6. To analyze Transcriptomics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transcriptomics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Transcriptomics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transcriptomics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Transcriptomics industry.

Chapter 3: Detailed analysis of Transcriptomics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Transcriptomics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Transcriptomics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Transcriptomics Industry Trends Table 2. Transcriptomics Industry Drivers Table 3. Transcriptomics Industry Opportunities and Challenges Table 4. Transcriptomics Industry Restraints Table 5. Global Transcriptomics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Transcriptomics Revenue Share by Company (2021-2026) Table 7. Global Transcriptomics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Transcriptomics Key Company Manufacturing Base & Headquarters Table 9. Global Transcriptomics Company, Product Type & Application Table 10. Global Transcriptomics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Transcriptomics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of PCR Table 15. Significant Companies of Microarray Table 16. Significant Companies of Sequencing Table 17. Global Transcriptomics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Transcriptomics Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Transcriptomics Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Transcriptomics Sales Value Share by Type (2021-2026) Table 21. Global Transcriptomics Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Pharmaceutical and Biotechnology Table 23. Significant Companies of Academic Research and Government Institutes Table 24. Significant Companies of Hospitals and Diagnostic Centers Table 25. Global Transcriptomics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Transcriptomics Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Transcriptomics Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Transcriptomics Sales Value Share by Application (2021-2026) Table 29. Global Transcriptomics Sales Value Share by Application (2027-2032) Table 30. Global Transcriptomics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Transcriptomics Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Transcriptomics Sales Value Share by Region (2021-2026) Table 33. Global Transcriptomics Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Transcriptomics Sales Value Share by Region (2027-2032) Table 35. Global Transcriptomics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Transcriptomics Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Transcriptomics Sales Value Market Share by Country (2021-2026) Table 38. Global Transcriptomics Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Transcriptomics Sales Value Market Share by Country (2027-2032) Table 40. Thermo Fisher Scientific Company Information Table 41. Thermo Fisher Scientific Business Overview Table 42. Thermo Fisher Scientific Transcriptomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Thermo Fisher Scientific Transcriptomics Product Portfolio Table 44. Thermo Fisher Scientific Recent Development Table 45. Illumina Company Information Table 46. Illumina Business Overview Table 47. Illumina Transcriptomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Illumina Transcriptomics Product Portfolio Table 49. Illumina Recent Development Table 50. QIAGEN (Exiqon) Company Information Table 51. QIAGEN (Exiqon) Business Overview Table 52. QIAGEN (Exiqon) Transcriptomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. QIAGEN (Exiqon) Transcriptomics Product Portfolio Table 54. QIAGEN (Exiqon) Recent Development Table 55. Agilent Technologies Company Information Table 56. Agilent Technologies Business Overview Table 57. Agilent Technologies Transcriptomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Agilent Technologies Transcriptomics Product Portfolio Table 59. Agilent Technologies Recent Development Table 60. Roche Company Information Table 61. Roche Business Overview Table 62. Roche Transcriptomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Roche Transcriptomics Product Portfolio Table 64. Roche Recent Development Table 65. GE Healthcare Company Information Table 66. GE Healthcare Business Overview Table 67. GE Healthcare Transcriptomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. GE Healthcare Transcriptomics Product Portfolio Table 69. GE Healthcare Recent Development Table 70. Bio-Rad Laboratories Company Information Table 71. Bio-Rad Laboratories Business Overview Table 72. Bio-Rad Laboratories Transcriptomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Bio-Rad Laboratories Transcriptomics Product Portfolio Table 74. Bio-Rad Laboratories Recent Development Table 75. Fluidigm Company Information Table 76. Fluidigm Business Overview Table 77. Fluidigm Transcriptomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Fluidigm Transcriptomics Product Portfolio Table 79. Fluidigm Recent Development Table 80. Research Programs/Design for This Report Table 81. Authors List of This Report Table 82. Secondary Sources Table 83. Primary Sources List of Figures Figure 1. Transcriptomics Product Image Figure 2. Global Transcriptomics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Transcriptomics Market Size (2021-2032) & (US$ Million) Figure 4. Global Transcriptomics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. PCR Image Figure 8. Microarray Image Figure 9. Sequencing Image Figure 10. Global Transcriptomics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Transcriptomics Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Transcriptomics Sales Value Share by Type (2021-2032) Figure 13. Pharmaceutical and Biotechnology Image Figure 14. Academic Research and Government Institutes Image Figure 15. Hospitals and Diagnostic Centers Image Figure 16. Global Transcriptomics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Transcriptomics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Transcriptomics Sales Value Share by Application (2021-2032) Figure 19. Global Transcriptomics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Transcriptomics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Transcriptomics Sales Value (2021-2032) & (US$ Million) Figure 22. North America Transcriptomics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Transcriptomics Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Transcriptomics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Transcriptomics Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Transcriptomics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Transcriptomics Sales Value (2021-2032) & (US$ Million) Figure 28. South America Transcriptomics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Transcriptomics Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Transcriptomics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Transcriptomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Transcriptomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Transcriptomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • PCR
  • Microarray
  • Sequencing
Applications
  • Pharmaceutical and Biotechnology
  • Academic Research and Government Institutes
  • Hospitals and Diagnostic Centers
Companies covered
  • Thermo Fisher Scientific
  • Illumina
  • QIAGEN (Exiqon)
  • Agilent Technologies
  • Roche
  • GE Healthcare
  • Bio-Rad Laboratories
  • Fluidigm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Transcriptomics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Transcriptomics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Transcriptomics Market Dynamics
  1. 2.1 Transcriptomics Industry Trends
  2. 2.2 Transcriptomics Industry Drivers
  3. 2.3 Transcriptomics Industry Opportunities and Challenges
  4. 2.4 Transcriptomics Industry Restraints
3 Transcriptomics Market by Company
  1. 3.1 Global Transcriptomics Company Revenue Ranking in 2025
  2. 3.2 Global Transcriptomics Revenue by Company (2021-2026)
  3. 3.3 Global Transcriptomics Company Ranking (2024-2026)
  4. 3.4 Global Transcriptomics Company Manufacturing Base and Headquarters
  5. 3.5 Global Transcriptomics Company Product Type and Application
  6. 3.6 Global Transcriptomics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Transcriptomics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Transcriptomics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Transcriptomics Market by Type
  1. 4.1 Transcriptomics Type Introduction
  2. 4.1.1 PCR
  3. 4.1.2 Microarray
  4. 4.1.3 Sequencing
  5. 4.2 Global Transcriptomics Sales Value by Type
  6. 4.2.1 Global Transcriptomics Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Transcriptomics Sales Value by Type (2021-2032)
  8. 4.2.3 Global Transcriptomics Sales Value Share by Type (2021-2032)
5 Transcriptomics Market by Application
  1. 5.1 Transcriptomics Application Introduction
  2. 5.1.1 Pharmaceutical and Biotechnology
  3. 5.1.2 Academic Research and Government Institutes
  4. 5.1.3 Hospitals and Diagnostic Centers
  5. 5.2 Global Transcriptomics Sales Value by Application
  6. 5.2.1 Global Transcriptomics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Transcriptomics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Transcriptomics Sales Value Share by Application (2021-2032)
6 Transcriptomics Regional Value Analysis
  1. 6.1 Global Transcriptomics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Transcriptomics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Transcriptomics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Transcriptomics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Transcriptomics Sales Value (2021-2032)
  7. 6.3.2 North America Transcriptomics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Transcriptomics Sales Value (2021-2032)
  10. 6.4.2 Europe Transcriptomics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Transcriptomics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Transcriptomics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Transcriptomics Sales Value (2021-2032)
  16. 6.6.2 South America Transcriptomics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Transcriptomics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Transcriptomics Sales Value Share by Country, 2025 VS 2032
7 Transcriptomics Country-level Value Analysis
  1. 7.1 Global Transcriptomics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Transcriptomics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Transcriptomics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Transcriptomics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Transcriptomics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Transcriptomics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Transcriptomics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Transcriptomics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Transcriptomics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Transcriptomics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Transcriptomics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Transcriptomics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Transcriptomics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Transcriptomics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Transcriptomics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Transcriptomics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Transcriptomics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Transcriptomics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Transcriptomics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Transcriptomics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Transcriptomics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Transcriptomics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Transcriptomics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Transcriptomics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Transcriptomics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Transcriptomics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Transcriptomics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Transcriptomics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Transcriptomics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Transcriptomics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Transcriptomics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Transcriptomics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Transcriptomics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Transcriptomics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Transcriptomics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Transcriptomics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Transcriptomics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Transcriptomics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Transcriptomics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Transcriptomics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Transcriptomics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Transcriptomics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Transcriptomics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Transcriptomics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Transcriptomics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Transcriptomics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Transcriptomics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Transcriptomics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Transcriptomics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Transcriptomics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Transcriptomics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Transcriptomics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Transcriptomics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Transcriptomics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Transcriptomics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Transcriptomics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Transcriptomics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Transcriptomics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Transcriptomics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Transcriptomics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Transcriptomics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Transcriptomics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Transcriptomics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Transcriptomics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Transcriptomics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Transcriptomics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Transcriptomics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Transcriptomics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Transcriptomics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Transcriptomics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Transcriptomics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Transcriptomics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Transcriptomics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Transcriptomics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Transcriptomics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Transcriptomics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Transcriptomics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Transcriptomics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Transcriptomics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Transcriptomics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Transcriptomics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Transcriptomics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Transcriptomics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Transcriptomics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Transcriptomics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Transcriptomics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Transcriptomics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Transcriptomics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific Transcriptomics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific Transcriptomics Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Illumina
  8. 8.2.1 Illumina Company Information
  9. 8.2.2 Illumina Business Overview
  10. 8.2.3 Illumina Transcriptomics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Illumina Transcriptomics Product Portfolio
  12. 8.2.5 Illumina Recent Developments
  13. 8.3 QIAGEN (Exiqon)
  14. 8.3.1 QIAGEN (Exiqon) Company Information
  15. 8.3.2 QIAGEN (Exiqon) Business Overview
  16. 8.3.3 QIAGEN (Exiqon) Transcriptomics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 QIAGEN (Exiqon) Transcriptomics Product Portfolio
  18. 8.3.5 QIAGEN (Exiqon) Recent Developments
  19. 8.4 Agilent Technologies
  20. 8.4.1 Agilent Technologies Company Information
  21. 8.4.2 Agilent Technologies Business Overview
  22. 8.4.3 Agilent Technologies Transcriptomics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Agilent Technologies Transcriptomics Product Portfolio
  24. 8.4.5 Agilent Technologies Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Transcriptomics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Transcriptomics Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 GE Healthcare
  32. 8.6.1 GE Healthcare Company Information
  33. 8.6.2 GE Healthcare Business Overview
  34. 8.6.3 GE Healthcare Transcriptomics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GE Healthcare Transcriptomics Product Portfolio
  36. 8.6.5 GE Healthcare Recent Developments
  37. 8.7 Bio-Rad Laboratories
  38. 8.7.1 Bio-Rad Laboratories Company Information
  39. 8.7.2 Bio-Rad Laboratories Business Overview
  40. 8.7.3 Bio-Rad Laboratories Transcriptomics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bio-Rad Laboratories Transcriptomics Product Portfolio
  42. 8.7.5 Bio-Rad Laboratories Recent Developments
  43. 8.8 Fluidigm
  44. 8.8.1 Fluidigm Company Information
  45. 8.8.2 Fluidigm Business Overview
  46. 8.8.3 Fluidigm Transcriptomics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Fluidigm Transcriptomics Product Portfolio
  48. 8.8.5 Fluidigm Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst